TSTessa Straatmijer

Tessa Straatmijer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tessa Straatmijer has a total of 127 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    New therapeutic options for metabolic‐associated steatotic liver disease

    by Tessa Straatmijer, Midas Mulder

    An increasing number of patients are being diagnosed with metabolic dysfunction‐associated steatotic liver disease (MASLD). MASLD results from disturbances in hepatic lipid metabolism and is associated with an increased risk of cirrhosis and hepatocellular carcinoma and significant extrahepatic morbidity, including cardiovascular disease and malignancies. The pathogenesis of MASLD stems from a multifactorial interaction among genetic susceptibility, epigenetic modifications and environmental factors, which collectively impair systemic metabolic homeostasis. Current management relies on a combination of lifestyle modification and pharmacotherapy. Resmetirom is the first drug registrated for the treatment of adults with MASLD and moderate to advances fibrosis. Over the next decade, multiple promising pharmacotherapies with diverse mechanisms of action and routes of administration are expected to become available for the treatment of MASLD. This narrative review provides an overview of the evolving pharmacological therapeutic landscape for MASLD, with a focus on novel therapeutic agents in late‐stage clinical development as THR‐β Agonists, GLP‐1 Receptor Agonists, Dual GLP‐1/ GIP Agonists, Glucagon/GLP‐1 Dual Agonists, FGF‐21 Analogues, Pan‐PPAR Agonists and FASN Inhibitors. Based on the differences in mechanisms of actions and specific side effects of these therapies, the characteristics of patients with MASLD should be taken into account in the decision which pharmacologic treatment should be initiated in an individual patient. Also, combining different therapies could be beneficial since this appears to possess complementary mechanisms.

  • Open Access

    Obesity Is Associated with Inferior Clinical Treatment Outcomes in Inflammatory Bowel Disease: A Nationwide Dutch Registry Study

    by Dorien Oomkens, Zlatan Mujagic, Annemarie de Vries, Andrea van der Meulen-De Jong, Tessa Straatmijer, Mark Löwenberg, Sander van der Marel, Rachel West, Alexander Bodelier, Fiona van Schaik, et al.

    Purpose To examine the impact of obesity on treatment outcomes in inflammatory bowel disease (IBD). Methods Patients aged ≥ 16 years, with IBD, a documented baseline body mass index (BMI), and starting thiopurines and allopurinol, intravenous (iv) vedolizumab, subcutaneous (sc) vedolizumab, ustekinumab, ozanimod, filgotinib, or tofacitinib were selected from the Dutch Initiative on Crohn and Colitis (ICC) registry. Underweight patients (BMI < 18.5 mg/kg2) were excluded. The primary outcome was steroid-free clinical remission (i.e. Simple Clinical Colitis Activity Index (SCCAI) ≤ 2 for ulcerative colitis (UC) and IBD-unclassified (IBD-U), and Harvey Bradshaw Index (HBI) < 5 for Crohn’s disease (CD)) at week 24. Remission rates were compared between normal weight (BMI 18.5–25 kg/m2), and overweight (BMI 25–30 kg/m2), and obese (BMI ≥ 30 kg/m2) patients using binary logistic regression analyses. Multivariable regression analysis was used to correct for possible confounders. Results Among 1066 patients with IBD, 619 had normal weight, 303 were overweight, and 144 were obese. At week 24, obese patients achieved steroid-free clinical remission less frequently (35.3%, OR = 0.578, 95% CI: 0.380–0.879, p = 0.010), supported by multivariable analysis (OR = 0.537, 95% CI: 0.346–0.832, p = 0.005). Conclusions Obesity was associated with lower steroid-free clinical remission at week 24. Obese patients with IBD should be encouraged to lose weight not only to improve their overall health, but also to optimize their treatment outcomes.


  • Open Access

    Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease

    by Tessa Straatmijer, Vince B. C. Biemans, Dirk Jan A. R. Moes, Frank Hoentjen, Rob ter Heine, P. W. Jeroen Maljaars, Rosaline Theeuwen, Marieke Pierik, Marjolijn Duijvestein, Andrea E. van der Meulen-De Jong, et al.

    Objective It is unknown whether ustekinumab (UST) levels can predict clinical outcomes in Crohn’s disease (CD) patients. We assessed the exposure–response relationship of UST trough concentrations with biochemical outcomes at week 24 in a prospective, real-world setting. Methods We performed a prospective study in patients with CD starting UST in four academic centres in the Netherlands. All patients received a weight-adjusted intravenous (IV) UST induction dose, followed by one subcutaneous (SC) dose of 90 mg UST at 8 weeks. Maintenance therapy consisted of 90 mg subcutaneous UST every 8 or 12 weeks. Individual UST concentration time course during treatment were estimated using a population pharmacokinetic (PK) model. Quartile analysis and logistic regression were performed to analyse if UST concentrations at week 8 were associated with biochemical remission rates at week 24 (C-reactive protein (CRP) ≤ 5 mg/L and / or faecal calprotectin (FC) ≤ 250 mg/kg). Results In total, 124 patients with CD were included. Patients achieving biochemical remission at week 12 and 24 had significantly higher UST levels at week 8 compared to patients without biochemical remission (6.6 µg/mL versus 3.9 µg/mL, P < 0.01 and 6.3 µg/mL versus 3.9 µg/mL, P < 0.01, respectively). In quartile analysis, patients with UST levels in the highest quartile (≥ 6.3 µg/mL at week 8) had higher biochemical remission rates at week 12 and week 24. There was no association between UST levels at and corticosteroid-free clinical remission rates. Conclusion In this real-world cohort of patients with CD, UST levels in the highest quartile (≥ 6.3 µg/mL) at week 8 were associated with higher biochemical remission rates at week 24.


  • Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in inflammatory bowel disease patients—authors' reply

    by Adriaan Volkers, Tessa Straatmijer, Marjolijn Duijvestein, Mark Löwenberg, Andrea van der Meulen, Geert D'HAens

    LINKED CONTENT: This article is linked to Volkers et al papers. To view these articles, visit https://doi.org/10.1111/apt.17153 and https://doi.org/10.1111/apt.17395


  • Open Access

    Effectiveness and safety of tofacitinib for ulcerative colitis: two‐year results of the ICC Registry

    by Tessa Straatmijer, Fiona D. M. van Schaik, Alexander G. L. Bodelier, Marijn Visschedijk, Annemarie C. de Vries, Cyriel Y. Ponsioen, Marieke Pierik, Ad A. van Bodegraven, Rachel L. West, Nanne K. H. de Boer, et al.

    Summary: Background: Tofacitinib is an oral Janus kinase (JAK) inhibitor and is registered for the treatment of ulcerative colitis (UC). The effectiveness of tofacitinib has been evaluated up to 12 months of treatment.Aim: The aim of this study was to assess the effectiveness and safety of 24 months of tofacitinib use in UC patients in the Netherlands.Methods: Patients initiating tofacitinib treatment were included in the ICC Registry, a nationwide, observational registry. Patients were prospectively evaluated for up to 24 months. The primary outcome was corticosteroid‐free clinical remission (CSFR, Simple Clinical Colitis Activity Index [SCCAI] ≤2) at week 104. Secondary outcomes included biochemical remission (C‐reactive protein (CRP) ≤5 mg/L and faecal calprotectin (FC) ≤250 μg/g), safety, and discontinuation rate.Results: We included 110 patients of whom 104 (94.5%) were anti‐TNF experienced. After 104 weeks of tofacitinib, 31.8% (34/107) were in CSFR, 23.4% (25/107) in biochemical remission and 18.7% (20/107) in combined clinical and biochemical remission. Of the patients in CSFR at week 52, 76.5% (26/34) remained so after 104 weeks of treatment. Sixty‐one patients (55.5%) discontinued tofacitinib after a median duration of 13 weeks (IQR 7–34). The main reasons for discontinuation were non‐response (59%), loss of response (14.8%), and adverse events (18%). There were 33.9 possible tofacitinib‐related adverse events per 100 patient‐years during follow‐up. Adverse events most probably related to tofacitinib were skin reactions and headaches. There were 6.4 herpes zoster infections per 100 patient‐years.Conclusion: Tofacitinib was effective in 31.8% of patients after 24 months of treatment.


  • Reply

    by Tessa Straatmijer, Andrea E. Van Der Meulen, Marjolijn Duijvestein


  • Open Access

    Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases

    by Adriaan Volkers, Tessa Straatmijer, Marjolijn Duijvestein, Amber Sales, Amit Levran, Fiona van Schaik, Jeroen Maljaars, Krisztina Gecse, Cyriel Ponsioen, Joep Grootjans, et al.

    Summary: Background: Subcutaneous (SC) vedolizumab is effective in inflammatory bowel diseases (IBD) when administered after induction with two infusions.Aim: To assess the effectiveness, safety and pharmacokinetics of a switch from intravenous (IV) to SC maintenance vedolizumab in patients with IBDMethods: In this prospective cohort study, patients with IBD who had ≥4 months IV vedolizumab were switched to SC vedolizumab. We studied the time to discontinuation of SC vedolizumab, adverse events (AEs), changes in clinical and biochemical outcomes and vedolizumab concentrations at baseline, and weeks 12 and 24.Results: We included 82 patients with Crohn's disease (CD) and 53 with ulcerative colitis (UC). Eleven (13.4%) patients with CD and five (9.4%) with UC discontinued SC vedolizumab after a median of 18 (IQR 8–22) and 6 weeks (IQR 5–10), respectively. Four patients with CD switched to a different drug due to loss of response, nine switched back to IV vedolizumab due to adverse events, and three due to needle fear. Common AEs were injection site reactions (n = 15) and headache (n = 6). Median clinical and biochemical disease activity remained stable after the switch. Median serum vedolizumab concentrations increased from 19 μg/ml at the time of the switch to 31 μg/ml 12 weeks after the switch (p < 0.005).Conclusions: Switching from IV to SC vedolizumab maintenance treatment is effective in patients with CD or UC. However, 9% of patients were switched back to IV vedolizumab due to adverse events or fear of needles.


  • Open Access

    Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study

    by Tessa Straatmijer, Vince B.C. Biemans, Marijn Visschedijk, Frank Hoentjen, Annemarie de Vries, Adriaan A. van Bodegraven, Alexander Bodelier, Nanne K.H. de Boer, Gerard Dijkstra, Noortje Festen, et al.


  • Open Access

    Letter: tofacitinib in treatment‐refractory ulcerative colitis—a single centre real‐world experience in Australia. Authors' reply

    by Vince B. C. Biemans, Tessa Straatmijer, Frank Hoentjen, Marieke J. Pierik

  • Ustekinuma b for Crohn’s Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study

    by Tessa Straatmijer, Vince B C Biemans, Frank Hoentjen, Nanne K H de Boer, Alexander G L Bodelier, Gerard Dijkstra, Willemijn A van Dop, Jeoffrey J L Haans, Jeroen M Jansen, P W Jeroen Maljaars, et al.

    Ustekinumab is a monoclonal antibody that selectively targets p40, a shared subunit of the cytokines interleukin [IL]-12 and IL-23. It is registered for the treatment of inflammatory bowel diseases. We assessed the 2-year effectiveness and safety of ustekinumab in a real world, prospective cohort of patients with Crohn’s disease [CD]. Patients who started ustekinumab were prospectively enrolled in the nationwide Initiative on Crohn and Colitis [ICC] Registry. At weeks 0, 12, 24, 52 and 104, clinical remission Harvey Bradshaw Index≤ 4 points], biochemical remission (faecal calprotectin ≤ 200 μg/g and/or C-reactive protein ≤5 mg/L], perianal fistula remission, extra-intestinal manifestations, ustekinumab dosage and safety outcomes were determined. The primary outcome was corticosteroid-free clinical remission at week 104. In total, 252 CD patients with at least 2 years of follow-up were included. Of all included patients, the proportion of patients in corticosteroid-free clinical remission was 32.3% [81/251], 41.4% [104/251], 39% [97/249] and 34.0% [84/247] at weeks 12, 24, 52 and 104, respectively. In patients with combined clinical and biochemical disease activity at baseline [n = 122], the corticosteroid-free clinical remission rates were 23.8% [29/122], 35.2% [43/122], 40.0% [48/120] and 32.8% [39/119] at weeks 12, 24, 52 and 104, respectively. The probability of remaining on ustekinumab treatment after 52 and 104 weeks in all patients was 64.3% and 54.8%, respectively. The main reason for discontinuing treatment after 52 weeks was loss of response [66.7%]. No new safety issues were observed. After 104 weeks of ustekinumab treatment, one-third of CD patients were in corticosteroid-free clinical remission.